{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:45:36Z","timestamp":1790390736831,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012462","name":"Office of Academic Affiliations, Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012462","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.eprac.2024.12.001","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T16:56:27Z","timestamp":1733504187000},"page":"366-372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Histopathologic and Clinical Features of Bethesda III-VI Nodules Harboring Isolated RAS Mutations"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4027-1123","authenticated-orcid":false,"given":"Young-Ji","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hattie H.","family":"Huston-Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max A.","family":"Schumm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xochitl R.","family":"Longstaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena G.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hong","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne S.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James X.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8436-392X","authenticated-orcid":false,"given":"Masha J.","family":"Livhits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.eprac.2024.12.001_bib1","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/cncr.31245","article-title":"Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules","volume":"124","author":"Nikiforova","year":"2018","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.001_bib2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1089\/thy.2023.0060","article-title":"Molecular testing predicts incomplete response to initial therapy in differentiated thyroid carcinoma without lateral neck or distant metastasis at presentation: retrospective cohort study","volume":"33","author":"Liu","year":"2023","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.eprac.2024.12.001_bib3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamasurg.2018.1153","article-title":"Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules","volume":"153","author":"Patel","year":"2018","journal-title":"JAMA Surg"},{"issue":"12","key":"10.1016\/j.eprac.2024.12.001_bib4","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1089\/thy.2022.0282","article-title":"Performance of a multigene genomic classifier in thyroid nodules with suspicious for malignancy cytology","volume":"32","author":"Skaugen","year":"2022","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.eprac.2024.12.001_bib5","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1210\/clinem\/dgad220","article-title":"Molecular profiling of 50 734 Bethesda III-VI thyroid nodules by ThyroSeq v3: implications for personalized management","volume":"108","author":"Chiosea","year":"2023","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2024.12.001_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoto.2023.1494","article-title":"Prognostic value of preoperative molecular testing and implications for initial surgical management in thyroid nodules harboring suspected (Bethesda V) or known (Bethesda VI) papillary thyroid cancer","volume":"149","author":"Schumm","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.001_bib7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40463-019-0372-5","article-title":"Molecular mutations as a possible factor for determining extent of thyroid surgery","volume":"48","author":"Krasner","year":"2019","journal-title":"J\u00a0Otolaryngol Head Neck Surg"},{"issue":"11","key":"10.1016\/j.eprac.2024.12.001_bib8","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1210\/clinem\/dgab286","article-title":"BRAF V600E status sharply differentiates lymph node metastasis-associated mortality risk in papillary thyroid cancer","volume":"106","author":"Tao","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.12.001_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejca.2019.10.017","article-title":"BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma","volume":"124","author":"Kim","year":"2020","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.eprac.2024.12.001_bib10","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1210\/jc.2005-0987","article-title":"BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer","volume":"90","author":"Xing","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"14","key":"10.1016\/j.eprac.2024.12.001_bib11","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAF\u00a0V600E\u00a0mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.001_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s12020-023-03633-y","article-title":"Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes","volume":"84","author":"Sim\u00f5es-Pereira","year":"2024","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.001_bib13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jnci\/djx227","article-title":"BRAF V600E mutation-assisted risk stratification of solitary intrathyroidal papillary thyroid cancer for precision treatment","volume":"110","author":"Huang","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.001_bib14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/cncy.22537","article-title":"RAS mutation and associated risk of malignancy in the thyroid gland: an FNA study with cytology-histology correlation","volume":"130","author":"Gilani","year":"2022","journal-title":"Cancer Cytopathol"},{"issue":"24","key":"10.1016\/j.eprac.2024.12.001_bib15","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.3390\/cancers13246194","article-title":"Advances in biomarker-driven targeted therapies in thyroid cancer","volume":"13","author":"Mishra","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.001_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.eprac.2024.01.002","article-title":"Molecular profiling for Bethesda III to VI nodules: results of a multicenter international retrospective study","volume":"30","author":"Morand","year":"2024","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.001_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/thy.2000.10.19","article-title":"N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression","volume":"10","author":"Basolo","year":"2000","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.001_bib18","first-page":"1010","article-title":"N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma","volume":"116","author":"Hara","year":"1994","journal-title":"Surgery"},{"issue":"8","key":"10.1016\/j.eprac.2024.12.001_bib19","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1634\/theoncologist.2013-0072","article-title":"RAS mutations in thyroid cancer","volume":"18","author":"Howell","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.001_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.001_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ecl.2014.02.010","article-title":"Update on differentiated thyroid cancer staging","volume":"43","author":"Momesso","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"15","key":"10.1016\/j.eprac.2024.12.001_bib21","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.3390\/cancers13153785","article-title":"Significance of RAS mutations in thyroid benign nodules and non-medullary thyroid cancer","volume":"13","author":"Marotta","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.001_bib29","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1089\/thy.2019.0116","article-title":"Utilities of RAS mutations in preoperative fine needle biopsies for decision making for thyroid nodule management: results from a Single-Center Prospective Cohort","volume":"30","author":"Guan","year":"2020","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.eprac.2024.12.001_bib35","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1210\/jc.2016-2620","article-title":"Clinical, sonographic, and pathological characteristics of RAS-positive versus BRAF-positive thyroid carcinoma","volume":"101","author":"Kakarmath","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.12.001_bib28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12916-015-0419-z","article-title":"The variable phenotype and low-risk nature of RAS-positive thyroid nodules","volume":"13","author":"Medici","year":"2015","journal-title":"BMC Med"},{"issue":"suppl 2","key":"10.1016\/j.eprac.2024.12.001_bib22","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1186\/1471-2482-13-S2-S44","article-title":"Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review","volume":"13","author":"Guerra","year":"2013","journal-title":"BMC Surg"},{"issue":"8","key":"10.1016\/j.eprac.2024.12.001_bib23","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1089\/thy.2014.0053","article-title":"NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma","volume":"24","author":"Jang","year":"2014","journal-title":"Thyroid"},{"issue":"7","key":"10.1016\/j.eprac.2024.12.001_bib24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/thy.2011.0261","article-title":"The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort","volume":"22","author":"Fukahori","year":"2012","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.001_bib25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/SLA.0000000000001420","article-title":"Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients","volume":"262","author":"Yip","year":"2015","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.eprac.2024.12.001_bib26","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/cncr.33421","article-title":"Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: a matched case-control study","volume":"127","author":"Yip","year":"2021","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.eprac.2024.12.001_bib34","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1210\/clinem\/dgae108","article-title":"Indolent behavior of malignant Bethesda III nodules compared to Bethesda V\/VI nodules","volume":"109","author":"Endo","year":"2024","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T18:50:02Z","timestamp":1741027802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24008577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1530891X24008577"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.12.001","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histopathologic and Clinical Features of Bethesda III-VI Nodules Harboring Isolated RAS Mutations","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}